Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7119929 in Advanced Liver Cancers and Solid Tumors
NCT04338685Phase 1Completed
- Sponsor
- Roche
- Start
- Jul 2020
- Primary completion
- Jan 2023
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of RO7119929 in hepatocellular carcinoma (HCC), biliary tract cancer (BTC), Metastatic liver cancer and 1 more (8 arms), sponsored by Roche. Primary endpoints: Dose-Limiting Toxicities at 14 months and Adverse Events at 14 months. Started Jul 2020; status: completed.
02
Drugs
RO7119929
03
Conditions
hepatocellular carcinoma (HCC)biliary tract cancer (BTC)Metastatic liver cancersolid tumor
Beyond the preview
Go deeper on NCT04338685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04338685.